By taking part in research you’ll be helping us to test and developed things like new models of care, support methods and drug treatments.

All of the studies you see below have been given approval by the Health Research Authority and will be carried out by experts with clinical, research and academic backgrounds.

The Adult Autism Spectrum Cohort – UK

Who this study is aimed at?

Adults aged 16 or older with a diagnosis of ASD

Who can’t take part?

People who do not have a confirmed diagnosis of ASD

Study summary

Questionnaire for people to be included in a cohort so that researchers can learn about the lives of adults on the autism spectrum

Study visits

One off questionnaire. Participants may be contacted in the future to be asked if they would like to take part in autism-related studies.

Services taking part

Autism Service, Michael Carlisle Centre

Who to contact

See website here.

How to contact

See website above.

TIME: Take home naloxone intervention multi centre emergency setting feasibility trial

Who this study is aimed at?

People who take opioid drugs such as heroin, morphine, fentanyl and methadone, and people who are friends or family members of a person at risk of opioid overdose

Who can’t take part?

Drug service users (or friends and family members of service users) who have no experience of opioid misuse

Study summary

One off interview lasting about 30-45 minutes or one off focus group lasting about 60 minutes

Study visits

One

Services taking part

Fitzwilliam Centre

Who to contact

Zoe Black

How to contact

zoe.black@shsc.nhs.uk

TACK - Adapting and testing a technology supported and solution-focused intervention (DIALOG+) for people with chronic depression

Who this study is aimed at?

People who have symptoms of depression or non-psychotic low mood with a duration of illness of at least 2 years and are receiving treatment from an NHS mental health service with regular contact with clinicians

Who can’t take part?

People who have a primary diagnosis of a substance misuse problem, a diagnosis of a mental disorder eg Alzheimer’s, current inpatients on a psychiatric ward.  People who do not currently have clinical contact with a mental health professional

Study summary

This research aims to develop a new approach to help people with chronic depression. Researchers have developed an intervention called “DIALOG+” which helped people with schizophrenia. DIALOG+ involved mental health staff using a tablet computer to ask about satisfaction with different areas of life and then working together to find solutions to concerns raised. After using DIALOG+, service users were more satisfied with life and had fewer symptoms. Service users and staff found the approach helpful and it saved the NHS money.

The second phase of the TACK programme is looking at the effectiveness of DIALOG+ for people with chronic depression on improving quality of life and clinical outcomes (such as depression symptoms). The intervention will be tested in routine meetings across six sites in England.  Researchers will also evaluate how cost-effective the intervention is within the NHS.  They will also determine what works well or not so well in order to improve training materials and resources for staff.

Study visits

Six months of monthly sessions, followed by six months of booster sessions, to be done at the same time as clinical appointments

Services taking part

Northlands Community Health Centre, Edmund Road, East Glade Centre

Who to contact

Matthew Mills, Shonagh Scott

How to contact

matthew.mills@shsc.nhs.uk, shonagh.scott@shsc.nhs.uk

Find out more

Find out more information here.

PPiP2: Prevalence of neuronal cell surface antibodies in patients with psychotic illness

Who this study is aimed at?

Service users aged 18-70 with symptoms of psychosis for longer than two weeks but less than two years

Who can’t take part?

Service users who have had psychotic symptoms for longer than two years

Study summary

Staff will collect a small sample of blood from you and other people with psychosis symptoms from across the country.  They will also collect some information about your symptoms and background.  If your blood test then shows that your immune system is not working properly they will discuss this with you. Researchers are exploring a possible treatment in a separate study called SINAPPS2 and you may be able to take part in this study.

Study visits

One visit of approximately 15 minutes

Services taking part

Limbrick Health Centre

Who to contact

Dr Raihan Talukdar, Alex Carey

How to contact

raihan.talukdar@shsc.nhs.uk, alex.carey@shsc.nhs.uk 

Find out more

Find out more information here.

The SPRINT study

Who this study is aimed at?

Adults who have previously been admitted to an acute mental health ward. Friends or relatives of these adults, who are willing to share further information with consent.

Who can’t take part?

Exclusion criteria include patients under the age of 18 years, over the age of 65 years and/or having no history of being a psychiatric inpatient.

Study summary

There has been little research into how common problems with social communication are in people who have been admitted to mental health wards, as well as their physical and mental health needs.

A research team at the University of Leicester has launched a study to learn more about these issues.

Study visits

The study will involve completion of autism-based questionnaire tests and an interview process

Services taking part

Limbrick Health Centre

Who to contact

Study Co-ordinator Hannah Gower

How to contact

Tel: 0114 2716315

Email: hannah.gower@shsc.nhs.uk

Hearing nasty voices: Developing new ways to measure the experience

Who this study is aimed at?

  1. Currently experience voices which threaten then or put them down (nasty voices)
  2. These voices must occur at least once per week
  3. Be aged 16 or older
  4. Be in contact with mental health services

Study summary

Hearing voices is one of the most common symptoms of schizophrenia. We aim to learn why some patients listen to and believe the content of distressing voices. This will enable the later development of psychological therapies which enable patients to disengage from distressing voice content.

Study visits

  1. A questionnaire that measures the amount that people i) Believe the things that nasty voices say; ii) Listen to nasty voices.
  2. A questionnaire that measures the reasons why people listen and believe nasty voices.    

Services taking part

Limbrick Health Centre

Who to contact

Dr Andrew Horan, Local Principal Investigator, Recovery Service North

How to contact

Email: Andrew.Horan@shsc.nhs.uk

Tel: 0114 271 6217

PREFER - Patient preferences for voice-hearing therapies

Who this study is aimed at?

You can take part if you are 16 years and over and have heard voices for at least six months. We would like to invite the following groups of people to take part: people who have and have not had psychological therapy in the past, people who do and do not have a mental health diagnosis.

Study summary

There are lots of different types of psychological (talking) therapies for the experience of hearing distressing voices. However, there hasn’t been any research about patient preferences for these therapies. We would like to find out more about your preferences, for example:

  • Practical things - like where you think therapy should take place. 
  • Techniques - what you think therapy should involve.
  • Outcomes - what you think therapy should focus on and try to help with. 

We want to be able to publish this information in scientific and healthcare journals and conferences. This will help clinicians and researchers to develop and offer therapies that better match with the patients’ preferences.    

Study visits

The study involves completing some questionnaires. These will include questions:

  • About you
  • About your voice-hearing and mental health experiences
  • About your therapy preferences
  • About and your thoughts and feelings about your life and future

Who to contact

Research Development Unit

How to contact

research.developmentunit@shsc.nhs.uk

BAN2401 - A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study with an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease

Who this study is aimed at?

Patients with a diagnosis of Alzheimer’s disease between the age of 50 to 90

Study summary

Many people may find their memory changes as they age. For most, it is a natural part of aging. For some however, it could be an indication of something more serious. For some, it could be Alzheimer’s Disease.

St Pancras Clinical Research is conducting a trial of an investigational drug for early stage Alzheimer’s, if you would like more information, please contact St Pancras Clinical Research at www.stpancrasclinicalresearch.com

Services taking part

Memory Service 

Who to contact

Amanda Bennett, Research Nurse

How to contact

Amanda.bennett@shsc.nhs.uk

Share this

Was this page useful?